Analysts Issue Forecasts for BioMarin Pharmaceutical Inc.’s FY2021 Earnings (NASDAQ:BMRN)

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) – Equities research analysts at William Blair decreased their FY2021 earnings estimates for shares of BioMarin Pharmaceutical in a research note issued on Monday, November 22nd. William Blair analyst T. Lugo now forecasts that the biotechnology company will post earnings of $0.26 per share for the year, down from their previous estimate of $0.29. William Blair has a “Outperform” rating on the stock. William Blair also issued estimates for BioMarin Pharmaceutical’s Q4 2021 earnings at ($0.17) EPS, Q1 2022 earnings at $0.01 EPS, Q2 2022 earnings at $0.09 EPS, Q4 2022 earnings at $0.28 EPS and FY2022 earnings at $0.57 EPS.

BioMarin Pharmaceutical (NASDAQ:BMRN) last issued its quarterly earnings data on Tuesday, October 26th. The biotechnology company reported ($0.20) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.25) by $0.05. The company had revenue of $408.74 million for the quarter, compared to the consensus estimate of $435.29 million. BioMarin Pharmaceutical had a net margin of 0.86% and a return on equity of 2.02%. The firm’s revenue for the quarter was down 14.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.29 earnings per share.

Several other equities analysts have also recently weighed in on BMRN. Credit Suisse Group raised their target price on shares of BioMarin Pharmaceutical from $100.00 to $105.00 and gave the company an “outperform” rating in a research note on Monday. SVB Leerink lifted their price objective on shares of BioMarin Pharmaceutical from $112.00 to $115.00 and gave the company an “outperform” rating in a report on Monday. Wedbush reiterated an “outperform” rating and set a $152.00 price objective on shares of BioMarin Pharmaceutical in a report on Thursday, October 28th. Zacks Investment Research downgraded shares of BioMarin Pharmaceutical from a “buy” rating to a “hold” rating and set a $81.00 price objective on the stock. in a research report on Tuesday, August 3rd. Finally, Guggenheim boosted their target price on shares of BioMarin Pharmaceutical from $103.00 to $120.00 and gave the stock a “buy” rating in a research report on Monday. Four equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $107.53.

BMRN opened at $89.57 on Wednesday. The firm’s 50 day simple moving average is $79.64 and its two-hundred day simple moving average is $79.49. The company has a current ratio of 4.49, a quick ratio of 3.03 and a debt-to-equity ratio of 0.25. The company has a market capitalization of $16.44 billion, a PE ratio of 1,119.63, a PEG ratio of 9.81 and a beta of 0.52. BioMarin Pharmaceutical has a 1-year low of $71.59 and a 1-year high of $92.57.

In related news, EVP Jeffrey Robert Ajer sold 2,739 shares of the business’s stock in a transaction that occurred on Tuesday, October 26th. The stock was sold at an average price of $73.60, for a total transaction of $201,590.40. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 1.69% of the company’s stock.

Several large investors have recently added to or reduced their stakes in BMRN. GWM Advisors LLC lifted its holdings in shares of BioMarin Pharmaceutical by 2.2% in the second quarter. GWM Advisors LLC now owns 6,356 shares of the biotechnology company’s stock valued at $530,000 after buying an additional 139 shares during the period. Torray LLC increased its position in BioMarin Pharmaceutical by 0.9% in the 2nd quarter. Torray LLC now owns 16,199 shares of the biotechnology company’s stock worth $1,352,000 after purchasing an additional 142 shares during the last quarter. Kistler Tiffany Companies LLC increased its holdings in shares of BioMarin Pharmaceutical by 15.1% during the 2nd quarter. Kistler Tiffany Companies LLC now owns 1,080 shares of the biotechnology company’s stock valued at $90,000 after acquiring an additional 142 shares during the last quarter. Commonwealth Equity Services LLC increased its holdings in shares of BioMarin Pharmaceutical by 0.5% during the 2nd quarter. Commonwealth Equity Services LLC now owns 31,626 shares of the biotechnology company’s stock valued at $2,638,000 after acquiring an additional 156 shares during the last quarter. Finally, Bbva USA increased its holdings in shares of BioMarin Pharmaceutical by 20.5% during the 3rd quarter. Bbva USA now owns 934 shares of the biotechnology company’s stock valued at $72,000 after acquiring an additional 159 shares during the last quarter. 94.28% of the stock is owned by institutional investors.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical, Inc engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. The company was founded by John C. Klock, Christopher M.

Read More: What is meant by buying and selling pressure?

Earnings History and Estimates for BioMarin Pharmaceutical (NASDAQ:BMRN)

Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.